It’s the end of the month--and the half year mark--so we open up today's monthly discussion with Nathan and Laura to include some of the headlines we’ve missed this year.
Last month a paper was published warning about the off target effects when using CRISPR. Laura and Nathan agree the kerfuffle which exploded into this month was more about Wall Street than adding anything new to science.
Remember the technology we used before CRISPR? Sangamo Biosciences launched the first ever “in vivo” (in human) trial for gene editing using Zinc Finger technology.
Also last month, the FDA approved a drug based on the genetic makeup of a tumor and not its location in the body. Nathan says, “Nyeh . . . And? Doctors have been doing it off label for years.” But Laura thinks it's more that just a symbolic gesture.
She also picked for her paper of the month this new study out by Robert Green’s group asking whether the benefits outweigh the risks for whole genome sequencing in healthy individuals.
"It’s preliminary, but it’s not PR. This is one of the really important questions for genomics in our time," says Laura.
Nathan highlights a paper propounding a new model for biology, the omnigenic model. Find out what that is in another fun and informative look back on the genomics headlines with Nathan Pearson and Laura Hercher.